The present study was undertaken to determine the mechanism whereby calcitropic hormones and mesenchymal stem cell progeny changes are involved in bone repletion, a regenerative bone process that restores the bone lost to calcium deficiency. To initiate depletion, weanling mice with a mixed C57BL/6 (75%) and CD1 (25%) genetic background were fed a calcium-deficient diet (0.01%) for 14 days. For repletion, the mice were fed a control diet containing 1.2% calcium for 14 days. Depletion decreased plasma calcium and increased plasma parathyroid hormone, 1,25(OH) 2 D (calcitriol), and C-terminal telopeptide of type I collagen. These plasma parameters quickly returned toward normal on repletion. The trabecular bone volume and connectivity decreased drastically during depletion but were completely restored by the end of repletion. This bone repletion process largely resulted from the development of new bone formation. When bromodeoxyuridine (BrdU) was administered in the middle of depletion for 3 days and examined by fluorescence-activated cell sorting at 7 days into repletion, substantial increases in BrdU incorporation were seen in several CD105 subsets of cells of osteoblastic lineage. When BrdU was administered on days 1 to 3 of repletion and examined 11 days later, no increases in BrdU were seen in these subsets. Additionally, osteocytes that stained positively for BrdU were increased during depletion. In conclusion, the results of the present study have established a unique regenerative mechanism to initiate bone repair during the bone insult. Calcium homeostatic mechanisms and the bone repletion mechanism are opposing functions but are simultaneously orchestrated such that both endpoints are optimized. These results have potential clinical relevance for disease entities such as type 2 osteoporosis. (Endocrinology 158: 714-729, 2017) 
T he sine qua non of survival is adaptation (1) . For a tissue, such as bone, to perform its functions, it must support a mechanism to maintain itself in response to duress. An example of a systemic duress is dietary calcium deficiency, which causes a large increase in bone resorption and bone loss to compensate for the lack of calcium in the diet. This is the well-understood hormonally mediated, adaptive homeostatic process of plasma calcium regulation (2) . Once mice are switched to a normal calcium diet, a rapid stimulation of bone formation occurs, leading to restoration of the bone lost during calcium deficiency. This adaptive process has been termed "bone repletion" (3) . The term "bone repletion" refers to a process of new bone formation and a smaller contribution of a mineralization of excess osteoid accumulated during the bone depletion phase. The term "bone depletion" refers to a process of enhanced bone resorption and the accumulation of unmineralized osteoid (4) .
Although the bone repletion phenomenon was recognized several decades earlier (3), the dominating scientific interest in bone at the time was how the bone participated in regulating serum calcium. However, the tandem bone repair mechanism of bone repletion that followed the experimental calcium deficiency was largely ignored. Accordingly, neither the significance of bone repletion nor the molecular mechanisms driving this repair process is well appreciated. However, the anabolic process of bone repletion is particularly interesting for several reasons: one reason is that the major deficit in the therapeutic armamentarium for osteoporosis is modalities capable of rejuvenating the skeleton. Bone repletion of itself is not a potential anabolic therapy, but it is a physiologic process characterized by a rapid and a large anabolic response. It is probably the largest osteoblastic bone formation response seen physiologically. Additionally and, intriguingly, mathematical evidence has shown that the amount of bone formed during bone repletion can completely restore (rejuvenate) the initial bony deficit (3) . Therefore, the process of bone repletion might constitute an investigative model to gain insight into the mechanism for rejuvenating the skeleton in cases of osteoporosis and other aspects of skeletal maintenance.
The mediators of the anabolic bone repletion response in rodents have not yet been established. Bone depletion during calcium deficiency is a systemic homeostatic mechanism to maintain plasma calcium. This is achieved through the hormonal feedback mechanisms involving appropriate increments in serum calcitropic hormones, parathyroid hormone (PTH), and 1,25(OH) 2 D (calcitriol) (2) . However, the level of both serum hormones quickly returns to normal once the normal calcium diet has been reinstituted. Because the plasma hormonal changes are not elevated during the anabolic response, we sought to test the hypothesis in weanling mice that the events occurring during the bone depletion phase are responsible for the subsequent anabolic response during bone repletion.
Although the mechanism of bone repletion is unclear, two features of the bone repletion process suggest that bone repletion is an adaptive regenerative mechanism to maintain bone tissue. First, the process of repletion functions to provide an endpoint of complete restoration (3) . Second, the osteoblastic anabolic response is proportional to the resorptive insult, such that the rate of bone formation during the repletion phase is proportional to the bone lost during depletion (3) .
The present study was a translational study undertaken to clarify the mechanism of bone repletion in young mice in an effort to better understand the bone reparative processes in adult humans. That the rodent model is suitable for potential extrapolation to human studies has been suggested by results showing that the process of bone repletion is similarly operable in normal humans (5) . Additionally, some indirect evidence has shown that the bone repletion regenerative mechanism might be dysfunctional in senile type 2 osteoporosis (6) (7) (8) . Consequently, animal studies could provide insight, not only on how to rejuvenate the osteoporotic skeleton, but also on senile osteoporosis. Other clinical bone entities possibly influenced by the bone repletion process include the mechanism whereby PTH therapy increases bone formation and the repletion of bone after parathyroidectomy for primary hyperparathyroidism (9) , which are presented in the discussion section.
Thus, bone repletion is a physiologic adaptive mechanism that involves a large increase in bone formation, is tightly regulated such that the depleted skeleton is completely rejuvenated, and is operable in normal young rodents and also in young healthy humans but could be subverted in some aged subjects. Therefore, we sought to clarify the molecular mechanisms responsible for this large osteoblastic response seen during bone repletion in our rodent model.
The seminal finding from the present study was that all the osteoblasts involved in replacing the lost bone during bone repletion were actually generated through hormonal activation of several subsets of mesenchymal stem cell (MSC) progeny during the calcium-deficient bone depletion phase. This, together with our other findings, has established bone repletion as a unique regenerative bone mechanism to protect the bone structure. Plasma calcium homeostasis and bone repletion are two opposing regulatory processes, but they function in such a manner as to collectively accomplish both corresponding goals. Accordingly, bone repletion is accomplished by a unique cellular mechanism that is not found in any other organ system in the body, with potentially important clinical implications for this mechanism, as would be expected from a highly conserved regenerative mechanism.
Materials and Methods
A more detailed description of some of the methods is provided in the Supplemental Methods section.
Animals and diets
Weanling mice with a mixed genetic background of C57BL/6 (75%) and CD1 (25%) were used. We chose this mouse strain because it is a common background for transgenic mice, and transgenic mice will be the major thrust to further explore the mechanism of bone repletion. This mouse strain exhibits a bone repletion response to a low calcium diet similar to that seen in the other strains of mice we have studied (10, 11) . The control diet contained 1.2% calcium and 0.4% phosphate. The bone depletion diet contained 0.01% calcium and 0.4% phosphate. The usual diet is 0.6% calcium. We, and others, have used 1.2% as a normal calcium diet (3, 10, 12) . We compared our results from previous studies in which we only used 0.6% calcium with those from the present study of 1.2% calcium and found the changes were similar (11) . The high calcium diet could have resulted in passive calcium transport. However, we found no statistically significant difference in the plasma calcium level between the control group of 4-week-old mice fed a diet containing 1.2% calcium and another control group of 4-week-old mice fed a regular rodent diet containing 0.6% calcium (11.2 6 0.3 vs 10.9 6 0.1 mg/dL; P . 0.05). Thus, the higher calcium content in the control diet did not affect the plasma calcium homeostasis. Our rationale for using a wide range of dietary calcium diets is that we sought to maximize the low calcium stress required to achieve large magnitude changes, which, in turn, would produce statistically definitive phenotypes without using a large number of mice. We knew that this extreme range is relevant to a more physiologic change because we have previously used different degrees of calcium deficiency and found a dose response in the repletion process (3). This approach also minimizes the chance of mild calcium deficiency in the control mice. A schema of the experimental design of calcium depletion/repletion is shown in Supplemental Fig. 1 . The mice were allowed free access to food and water and were kept under a 12-hour light/12-hour dark cycle. The institutional animal care and use committee of Loma Linda University and the Animal Care and Use Review Office of the US Department of Army approved the animal care and use component of the present study.
Plasma parameter measurements
Plasma PTH, 1,25(OH) 2 D, C-terminal telopeptide of type 1 collagen (CTX), and procollagen type 1 N-terminal propeptide (P1NP) were determined, as described previously (10) . Plasma calcium was determined by the Heartland Assays Laboratory (Ames, IA).
Micro-computed tomography analyses
The bone parameters of fixed femurs were analyzed using micro-computed tomography (m-CT) with a Scanco VivaCT 40 instrument (Scanco Medical AG, Brüttisellen, Switzerland), as previously described (13) .
Bone histomorphometry and histologic features
Static and dynamic bone histomorphometry of femurs and histologic features were determined, as previously described (14) . The nomenclature and definition of the bone histomorphometry parameters followed those recommended by the 2012 American Society for Bone and Mineral Research histomorphometry nomenclature committee (15) .
Flow cytometry (fluorescence-activated cell sorting) analysis
In brief, bone marrow cells, after the red blood cells had been lysed with red blood cell lysis buffer, were preblocked with 1 mg/ million cells of mouse BD Fc blocker (BD Biosciences, San Jose, CA) at 4°C. The cells were first stained for viability with fixable viability dye eFluor 780 dye (eBioscience, San Diego, CA) for 30 minutes at 4°C and then for the various surface markers using the respective specific fluorescent-conjugated specific antibodies (i.e., CD45-PerCP, CD90-APC, CD29-PE, and CD105-PeCy7; purchased from eBioscience or BD Biosciences) at 4°C for 30 minutes. After fixation, the cells were incubated with the unconjugated primary antibody against mouse osteocalcin, sox9 (Santa Cruz Biotechnology, Dallas, TX), or osterix (Abcam, Cambridge, MA), followed by either phycoerythrin-or fluorescein isothiocyanate-conjugated secondary antibodies (eBioscience) at room temperature for 30 minutes. Proliferating cells were defined by the expression of Ki67 (16) or the incorporation of bromodeoxyuridine (BrdU) into DNA (17) and detected by anti-Ki67-PerCP-eFluor710 or anti-BrdU-fluorescein isothiocyanate (eBioscience). Genomic DNA of the cells was denatured with DNase (Roche, San Diego, CA) before immunostaining for BrdU. We used the FlowJo, version 10 (Ashland, OR; www.flowjo. com), software to analyze the fluorescence-activated cell sorting (FACS) data. The source of the antibodies used in this study is listed in Supplemental Table 1 .
For FACS analysis of osteoblastic fractions, bone samples, after flushing out the bone marrow cells, were digested with 2 mg/mL collagenase for 90 minutes at 37°C to release bone surface osteoblasts, as previously described (18) . The isolated osteoblasts were first stained for viability with fixable viability dye eFluor 780 viable dye as described in the previous paragraph, followed by incubation with anti-CD45-PerCP antibody to distinguish the marrow cells from isolated osteoblast fractions. BrdU + Runx2 + , BrdU + Osx + , and BrdU + Ocn + osteoblast subsets of cells were then analyzed using a FASC strategy similar to that described previously for bone marrow cells. The percentage of positive osteoblasts after the elimination of dead and/or CD45 With respect to stem cell nomenclature, we evaluated mesenchymal cells only by FACS analysis, and the cells were not available for further in vitro trilineage study. Because we did not apply sufficient number of markers to be able to distinguish MSCs from progeny, in the present study, we applied the term CD105 + stromal cells to describe the mesenchymal cell progenies quantitated during the study.
The percentage of CD45 2 bone marrow fraction after the elimination of dead cells was approximately 36% (see Fig. 4 ). The percentage of osteoblasts in the digested bone fraction was ;99%.
Quantitative Reverse Transcription Polymerase Chain Reaction
Total RNA extraction from the tibia and quantitative reverse transcription polymerase chain reaction (PCR) of the test genes were performed as previously described (10) . The sequence of PCR primers for the test genes is presented in Supplemental Table 2 .
Immunofluorescence staining
In brief, the femur, after fixation with Zamboni's fixative for 12 hours at 4°C, was embedded in an embedding medium (SECTION-LAB, Co., Ltd., Hiroshima, Japan). Frozen thin sections (7-mm thick) were then prepared with a Leica cryostat, and mounted onto a plastic film (Cryofilm type IIC, SECTION-LAB). The frozen sections were stored in 100% ethanol at 220°C until immunofluorescence staining. To visualize BrdU + cells, the bone sections were first digested with proteinase K for 10 minutes, followed by 20 minutes of treatment with 2N HCl to denature the DNA (19) . After rinsing, the sections were preblocked with 10% nonimmune serum and incubated at 4°C overnight with a rat anti-mouse BrdU antibody (Abcam). The fluorescence signal was developed with Alexa Fluor 555 anti-rat IgG (Molecular Probes, Eugene, OR) for 1 hour. The stained section was then cover-slipped with the anti-fade mounting medium containing 4 0 ,6-diamidino-2-phenylindole (to label the nuclei) as the counterstain (Vector Laboratory, Burlingame, CA). For the paraffin sections, heat retrieval was applied before staining for BrdU.
The blood vessels within the bone marrow cavity were visualized by immunofluorescent staining of a well-known cell surface marker of endothelium (von Willebrand factor [vWF]) on thin frozen longitudinal femoral sections using the same approach as described, with the rabbit anti-mouse vWF antibody (Dako, Carpinteria, CA) as the primary antibody and Alexa Fluor 555 anti-rabbit IgG (Molecular Probes).
Tartrate-resistant acid phosphatase histochemical staining
Histochemical staining of tartrate-resistant acid phosphatase (TRAP) on thin paraffin sections of the femur was performed, as previously described (12) .
Statistical analysis
All results are presented as the mean 6 standard error of the mean (SEM). Statistical significance was determined using twotailed Student t test. The difference was considered statistically significant at P , 0.05.
Results
Our results were obtained from weanling mice. It is important to note that mice, in contrast to humans, do not undergo osteonal remodeling.
Effects of dietary bone depletion and bone repletion on plasma parameters
Just as in previous reports (10, 11), a substantial decrease in plasma calcium was found 14 days after the mice began consuming the low calcium diet [ Fig. 1(a) ]. Once calcium was returned to the diet, a substantial increase in plasma calcium (compared with the plasma calcium level during depletion) was found, with a return to normal by day 7 of repletion. Plasma PTH [ Fig The finding of decreased plasma calcium in our study is somewhat in conflict with the concept advanced by Eisman and Bouillon (20) that, in general, serum calcium is usually maintained by homeostatic mechanisms, with which we agree. In support of this concept, the serum calcium in patients with secondary osteoporosis was , and (e) P1NP (n = 5 to 12) were determined after 14 days of dietary bone depletion or after bone repletion for 3 days (3d), 6 days (6d), or 14 days (14d). Data are shown as mean 6 SEM; *P , 0.05; **P , 0.01; ***P , 0.001 vs respective controls by two-tailed Student t test.
slightly decreased (albeit in the normal range) but was attended by a large increase in serum PTH (21) . It seems likely that the low calcium stress was present for a long period, allowing the parathyroid glands to enlarge and thereby maintain serum calcium levels. However, an exception to this position is our finding from a clinical study of normal young adults, who developed a mild, but clinically significant, decreased plasma calcium level, attended by an increase in serum PTH, in response to an acute induction of a low calcium diet (,300 mg/d) for 14 days (5). That finding suggested that an acute induction of a very low calcium diet can lead to decreased plasma calcium.
In the present study, an additional explanation for the decreased plasma calcium was that the 4-week-old mice were rapidly growing and were at the steep portion of the growth curve (22) . The mice actually gained about 15% of their total body weight during the 14-day experimental period, during which time one would expect to see an increase in the length and breadth of the skeletal components. At the end of 14 days of depletion, the control mice had gained an average of 2.99 g, which was not significantly different from the average weight gain of the calcium depletion group (2.95 g). Additionally, the femoral bone length between the control and depletion groups was not significantly different (13.2 6 0.1 vs 13.3 6 0.1 mm).
The decreased plasma calcium level observed in our study was also different from the results of a study with an intestinal vitamin D receptor (VDR) deletion (23) , in which mineralization was actively suppressed, together with increased bone resorption, allowing the maintenance of normal serum calcium homeostasis. Several serum differences were present between the two studies. For example, in our study compared with the intestinal VDR knockout study, the increases in plasma 1,25(OH) 2 D and PTH were much greater and serum phosphate was elevated (10) . We speculate that in our study, the hormones recruited to maintain serum calcium also led to an increase in serum phosphate (a change we also found in an earlier study of bone repletion [10] ); namely, the markedly elevated plasma 1,25(OH) 2 D and markedly depressed fibroblast growth factor-23, which we also documented in a previous study of bone repletion (10) . Thus, an increased phosphate load from the bone, gut, and kidney occurred, relative to the intestinal VDR knockout study. An oral phosphate load has been shown to increase serum phosphate and PTH but decrease serum calcium (24) . This effect of phosphate load to reduced serum calcium would tend to limit the amount of correction of the low serum calcium in our study. Clearly, more work is necessary to better understand the mechanism of the tandem regulation of serum calcium and phosphate when the kidney is the only organ that differentially regulates the two elements in response to compensatory challenges.
Effects of dietary bone depletion and bone repletion on osteoclastic and osteocytic bone resorption After 14 days consuming the calcium deficient diet, histomorphometric studies revealed an increase in the number of osteoclasts per bone surface [ Fig. 2(b) ]. This indicates that a preponderance of osteoclasts over osteoblasts was present on the existing bone surface. However, this does not represent the peak bone resorption in our trabecular sampling site, because the bone at the site had already been resorbed, as described in the next section on m-CT. Consequently, the total bone area surface, which was the referent for the osteoclast counts, was significantly decreased (0.064 6 0.005 mm 2 vs 0.087 6 0.008 mm 2 ; P , 0.05). The increase in osteoclast number was attended by an increase in intensity of TRAP staining compared with the control sections, which could reflect an increase in the resorptive activity for osteoclastic cells [ Fig. 2(a) ].
We also evaluated TRAP staining in osteocytes. Positive TRAP staining in osteocytes was significantly greater in the depletion group than in the control group and almost exclusively located in the region of intense osteoclastic bone resorption [ Fig. 2(c) ]. This is consistent with our earlier finding using mercury porosimetry and intrusion to evaluate osteocytic and osteoclastic bone resorption (25) . The amount of TRAP staining was much more intense and widespread for the osteoclasts than for the osteocytes. Mercury porosimetry (which is probably the most accurate measurement of osteocytic bone resorption) showed that osteoclastic net bone resorption was 24 times greater than osteocytic bone resorption in response to a systemic stimulus of bone resorption (26) . The colocalization of the two resorptive processes suggests that osteoclastic and osteocytic bone resorption act in concert to resorb bone. In addition, by visual inspection, the number of apoptotic osteoclasts in the bone depletion group appeared to be greater than the number in the control group at the end of depletion (data not shown). This finding is consistent with our previous study in which this event was quantitated (12) .
Effects of dietary bone depletion and bone repletion on cortical and trabecular bone by m-CT
In previous studies, our focus on bone lost during calcium depletion was on cortical bone (3, 11) . However, in the present study with access to m-CT, we were able to discern that the trabecular bone loss was .40% and cortical bone loss was only 5% during the 14-day period of calcium deficiency (Fig. 3) . The trabecular bone volume per tissue volume changed from 242% during the 14 days of bone depletion to +4% during the 14 days of bone repletion. Also remarkable was the finding that trabecular connectivity, which was decreased by about 40% during bone depletion, had completely returned to normal after 14 days of a calcium-sufficient diet. The bone repletion model could represent a physiologic model to study the mechanism of trabecular connectivity, which is poorly understood. Cortical porosity was not spared during the calcium deficiency phase, and was increased by .25% during bone depletion, partially returning toward normal by the end of calcium repletion. All the trabecular bone parameters had returned to normal by the end of the bone repletion period. The cortical parameters had not entirely returned to normal by 14 days. However, our previous studies indicated that complete restoration eventually occurs, at least in young adult rats (3). Our sampling site for the histologic studies, described in the following section, in the femur was trabecular bone, because the m-CT analysis showed that much more trabecular bone was lost than cortical bone during low dietary calcium stress.
Effects of dietary bone depletion on osteoblasts, matrix formation, and mineralization
Another process occurring simultaneously with the high level of bone resorption during bone depletion was the accumulation of multiple layers of osteoblasts near the resorption sites [ Fig. 4(a) ]. This was the most seminal observation of the present study. Consistent with the appearance of very large, highly active-appearing osteoblasts, the matrix apposition rate was increased by 35% (Table 1) . Mathematical evidence for multiple layers of osteoblasts was the finding that the number of osteoblasts (N.Ob) per osteoblastic surface had significantly increased [ Fig. 4(c) ]. However, the increase in N.Ob was not distributed uniformly along the bone surface but rather in clumps [ Fig. 4(a) ]. In the bones from the mice at the end of bone depletion, the frequency of multiple vs single layers of osteoblasts adjacent to wide osteoid was 64.4 6 2.5 vs 35.6 6 2.5 (P , 0.0001). These results are consistent with the interpretation that the effect of osteoblasts to regulate mineralization is independent of the effect of osteoblasts to regulate matrix production.
Although an increase occurred in the N.Ob in the bone depletion group, the actual amount of mineralized bone formed during depletion was decreased (as would be expected to support serum calcium homeostasis; Table 1 ). The decrease in bone formation was largely due to a decrease in tetracycline labeled surface (Table 1) , reflecting a decrease in the number of actively mineralizing osteoblasts.
Consistent with the elevated plasma P1NP, at the end of depletion, histomorphometric measurements of matrix formation showed a 24% increase (Table 1) . That the osteoblasts were active in matrix synthesis is consistent with the large increase in osteoblast size illustrated in Fig.  4(a) . In aggregate, these observations suggest that bone matrix formation was increased during depletion. At first, this might seem inappropriate; however, in fact, it represents an important part of the bone repletion mechanism. Accordingly, although the matrix formation was increased, the mineralized bone formation rate was decreased because a substantial inhibition of osteoblastic mineralization of osteoid was present, with a resulting increase in unmineralized osteoid [ Fig. 4(b) and 4(d) ].
The functional significance of the excess osteoid is that this unmineralized osteoid rapidly mineralizes when dietary calcium is normalized and, as such, would contribute to the overall gain in mineralized bone. Accordingly, we calculated the contribution of new bone formation (about 85%) vs mineralization of the excess osteoid (about 15%) to the overall gain in mineralized bone at the end of bone repletion (Supplemental Fig. 2 ). To be certain of the quantitative importance of these two processes on bone repletion, we calculated the percentage of contribution by each using the same formula but two different data inputs (Supplemental Fig. 2 ). Despite the finding that during depletion the osteoblasts were overactive in producing matrix (i.e., bone collagen), the same cells were underactive in supporting bone matrix mineralization.
With respect to the potential mechanisms for the impaired mineralization, we measured messenger RNA of Enpp1, Enpp3, Ank, and Opn, all of which are known to be inhibitory in the mineralization process and all of which were increased at the end of bone depletion (Supplemental Fig. 3) . Because of the impairment in bone mineralization, one might expect to find rickets; however, in a previous bone repletion study, we found no impairment of bone growth in length (10).
Effect of dietary bone depletion on the population of MSCs and progenies
A robust increase in the N.Ob during dietary calcium depletion led to our hypothesis that this buildup of osteoblasts was at least in part due to the proliferation and differentiation of MSCs toward the osteoblastic lineage during the bone depletion phase. Thus, we examined the marrow compartment for the possible source of increased osteoblast lineage cells during calcium depletion using FACS analysis. We examined four mesenchymal cell/ stromal cell subsets of CD45 This was unexpected because of previous work indicating that CD90 + cells are osteoblast precursors under certain conditions (27) . An increase in Sox9 + cells during calcium depletion is consistent with recent data showing that PTH stimulates Sox9 + osteoprogenitors/osteoblasts (28) . All four subsets of MSCs studied are known from published data to express PTH receptors (29, 30) , suggesting that elevated PTH was at least a partial contributor to the observed mesenchymal lineage cell proliferation.
To further explore mesenchymal cell proliferation and differentiation, mice were injected with BrdU daily for 3 days beginning on day 7 of the 14-day calcium depletion. BrdU would be expected to label most proliferating MSCs and osteoprogenitors at the time the label was administered. We then isolated the osteoblasts after 7 days of dietary calcium restoration (i.e., 11 days later) for FACS analysis. FlowJo analysis showed that in osteoblasts, a substantial increase had occurred, greater than the control values, in the individual populations of BrdU + osteoblastic fraction expressing Runx2, osterix (Osx), or osteocalcin (Ocn) [ Fig. 6(b) ]. Also, a substantial increase was found in the percentage of BrdU + osteocytes determined by immunohistochemistry (IHC) [ Fig. 6 (a) and 6(c)]. Therefore, from our FACS and IHC data, we can conclude that an increase in cell proliferation occurs in mesenchymal lineage cells, leading to an accumulation of mature osteoblasts during calcium restriction. These osteoblasts, which accumulated in the phase of calcium restriction, would be expected to be subsequently involved in the bone repletion process. The increased accumulation of osteoblasts was attended by more BrdU + osteocytes during the bone repletion process when calcium had been reinstituted in the diet. These FACS and IHC data are consistent with an increase in proliferation and differentiation of MSCs toward osteoblasts and osteocytes.
At this point, we had evidence that the increase in osteoblasts during bone depletion was at least partially contributed to by enhanced mesenchymal cell activities during bone depletion. However, this did not exclude the possibility that an increase also occurred in the proliferation of osteoblast progenitors early on during bone repletion. To examine this further, we performed a BrdU tracking study during bone repletion. If an unknown factor was operative to enhance osteoprogenitor cells, we would expect an increase in BrdU-labeled osteoblasts during repletion. The mice were labeled with BrdU during the first 3 days of repletion, and the osteoblasts fraction was obtained and examined for BrdU incorporation at the end of the 14-day calcium repletion (i.e., 11 days later). However, no increase in BrdU incorporation was found in the subsets of osteogenic cells, including those expressing Runx2, Osx, or Ocn [ Fig. 6(d) ].
Because a considerable amount of trabecular bone was removed from the marrow space (Fig. 3) , we examined it for residual osteoblasts. We found no sites in the marrow space in which osteoblasts without trabecular bone spicules were identifiable. We examined BrdU expression in marrow cells and were unable to identify any identifiable isolated osteoblasts in the marrow space expressing BrdU. Nonetheless, we speculate that without physical attachment to the matrix (31), the isolated osteoblasts dedifferentiated and thus were no longer identifiable as osteoblasts. According to this concept, some of the marrow BrdU + cells could have been dedifferentiated osteoblasts. As such, the osteoblasts could have dedifferentiated after the spicule was removed and then redifferentiated to participate in the formation of new trabecular bone during repletion. This would be consistent with the concept of cellular reprogramming to accurately replace the depleted bone. This important issue will require further investigation to resolve.
However, such dedifferentiated osteoblasts could have resulted in mesenchymal cell proliferation because dedifferentiated osteoblasts are not necessarily a prerequisite for de novo trabecular bone formation. Also, we have seen de novo bone formation with our engineered stem cell therapy for bone augmentation in which de novo bone formation is seen at sites in the marrow where no bone previously existed (13) .
Additionally, because considerable cell migration activity occurs during the processes of bone depletion and bone repletion, we examined, by real-time PCR analysis, six different migration factors, osteopontin (32), MMP9 (33) , S1P (through measurements of the enzyme that synthesizes S1P, [SphK1]) (34), SDF-1 (35), PDGF-AA (36) , and PDGF-BB (37) for a possible increase. All these migration factors were increased during bone depletion and returned to normal or toward normal during bone repletion (Supplemental Fig. 5 ). In aggregate, these observations are inconsistent with a contribution of the bone repletion phase of enhanced osteoblast precursor cell proliferation. Therefore, we concluded that all the additional cells needed for bone repletion were produced during the bone depletion phase.
Effect of dietary bone depletion on the number of vWF + vessels by IHC Because the demand was high for the precursors of osteoclasts and osteoblasts during calcium depletion, we sought to determine whether an increase occurred in angiogenesis to serve the increase in cellular activity. We stained bone specimens immunohistochemically with a specific antibody for vWF, a cell surface component of endothelium (38) . As shown in Supplemental Fig. 6 , the number of vWF + vessels was significantly increased by .30% after 14 days of calcium depletion, suggesting that the number of blood vessels was increased in response to dietary calcium restriction.
Discussion

A concept for bone tissue regeneration
Plasma calcium regulation is a homeostatic mechanism that is well recognized (2) . This same mechanism is a component of another homeostatic mechanism-the bone repletion mechanism, which acts to maintain bone tissue. These two regenerative mechanisms act simultaneously to accomplish their respective endpoints effectively and rather elegantly. In contrast to plasma calcium regulation, the bone repletion mechanism is not well understood. However, bone repletion has been demonstrated in mice (10, 11) , rats (3, 12, 39) , and humans (5), indicating that this adaptive bone process is evolutionally conserved and therefore essential for livelihood. We speculate that these two regenerative mechanisms began to evolve 285 million years ago (40) , with the migration of species from the aquatic environment to land, where calcium availability is much less than that in the ocean, requiring conservatory mechanisms. The lack of understanding of the process of bone repletion formed the basis for the present study. We sought to amplify our knowledge of the cellular phenotypic changes characteristic of bone repletion. Our results should be interpreted with the appreciation that they were obtained from weanling, rather than adult, mice. However, we have previously shown that adult humans also respond to calcium deficiency with a bone repletion response (5) .
The most salient finding from the present study was that, during the bone depletion phase, a stockpiling occurred of osteoblastic lineage cells, which acted to correct the bone lost during calcium deficiency-induced bone depletion. Based on these data, we advance the concept that bone tissue exhibits a unique renewal mechanism, whereby the osteoblasts required to replace the bone lost during bone depletion are created and stockpiled to be rapidly deployed during a period of calcium sufficiency. The details of this concept are illustrated in Fig. 7 and discussed later. According to this model, during bone depletion, an approximately appropriate number of osteoblast-like cells will be generated, simultaneously as bone is resorbed by osteoclasts. The number of osteoblastlike cells generated in effect constitutes an approximate memory of the amount of bone that is lost and must be replaced.
Critical to the validity of our concept is our dynamic data on CD45 2 CD105 + lineage cells. Two different subsets of these cells showed substantial increases in Ki67 positivity: the CD29 + and Osx + subsets, indicating that these subfractions were proliferating more rapidly than the controls at the end of the bone depletion phase. Moreover, a BrdU pulse-chase experiment was performed to evaluate osteoblast lineage cell dynamics. When BrdU was administered at the midpoint of the bone depletion phase, three different osteoblastic subsets were significantly increased in BrdU positivity on the seventh day of bone repletion, including those expressing Runx2 (increased 1000%), Osx, or Ocn. Finally, a substantial increase in the percentage of BrdU + osteocytes was found. The latter finding is a particularly decisive event to support accelerated differentiation of the osteoblast lineage cells. Together, these data are consistent with the https://academic.oup.com/endointerpretation that during bone depletion an increase occurs in the proliferation of certain subsets of mesenchymal lineage cells, accompanied by their osteogenic differentiation and migration toward the bone surface, where they remain until the dietary calcium has been normalized. This accumulation of reparative cells, during the insult to the bone structure from calcium deficiency, is a unique homeostatic repair process that, to the best of our knowledge, does not generically operate in any other repair/maintenance process in the body.
Molecular mechanisms for the increase in proliferation and differentiation of mesenchymal lineage cells during dietary bone depletion
The accumulation of osteoblast lineage cells during bone depletion (Fig. 7, left) could result from the attending increases in plasma calcium regulating hormone or the increase in mechanical stress that developed as a consequence of the bone lost during the imposed calcium deficiency. We have previously excluded the mechanical stress mechanism (39) . Accordingly, complete immobilization of the hindlimb does not impede the bone repletion process. Thus, bone repletion is likely a systemic process that requires circulating factors to be implemented. The most obvious plasma changes during depletion are decreased calcium, increased PTH, and increased 1,25(OH) 2 D (Fig. 1) . Sufficient published data are available on the activities of these two calcitropic hormones to invoke the participation of these two hormones in the observed cellular changes during bone depletion (5, 10). Accordingly, osteocytes (which express receptors for both hormones) respond to these two hormones with an increase in RANKL (41, 42) , which, in turn, leads to a marked increase in osteoclastic bone resorption (43, 44) . Both hormones, in particular, PTH, have well-established actions to increase MSC proliferation and differentiation (45, 46) . MSCs and osteoblast lineage cells express receptors of both hormones (47, 48) . 1,25(OH) 2 D is a strong cellular differentiation hormone for osteoblasts, as well as other cells (49, 50) . However, high levels of 1,25(OH) 2 D also inhibit bone mineralization (51) .
Although the proliferative action of PTH is well documented, the potential role of 1,25(OH) 2 D in bone repletion is more complicated. It has been shown that in a postlactation mouse model, the knockout of the VDR does not impair bone repletion (two major physiologic causes of calcium deficiency exist, a calcium deficient diet and lactation, which probably share some common mechanisms, as discussed further). With respect to the low serum calcium in our study and the normal serum calcium in the lactation study, the lactating mice were in the slow portion of the growth curve. In contrast, our mice were in the steep portion of the growth curve. Additionally, bone resorption in lactation was increased by an elevated PTH-related protein (PTHrP), a hormone that is regulated differently than PTH (52) .
Although the VDR knockout result was wellestablished (53) , uncontrolled variables could have influenced the interpretation. The serum 1,25(OH) 2 D levels in the VDR knockout mice were most likely extremely high, and a membrane receptor has been described for this hormone (54) . However, the biological significance of such a receptor is controversial (55) . Moreover, in the VDR knockout study, large differences were present in the mineral content of the diets for the control and VDR knockout mice. Thus, the possibility exists that 1,25(OH) 2 D plays an important role in the bone repletion process.
Our proposed hormonal mechanisms do not rule out some other unknown mediators in the bone repletion response. Several studies have raised the possibility that the anabolic effects of PTH do not simply result from PTH alone (56) . Previous in vivo and in vitro studies have indicated that PTH can lead to an increase in Wnt production (57) and signaling through suppression of osteocytic production of Sost (58) . That targeted ablation of the PTH/PTHrP receptor in osteocytes impaired the homeostatic calcemic responses (59) strongly supports a key role of the PTH action on osteocytes. Additionally, the effect of calcium-regulating hormones to increase bone resorption could release physiologic amounts of growth factors, such as transforming growth factor-b and insulin-like growth factor 1, from the bone matrix (60, 61) . Other studies have shown that conditioned medium from PTH-treated cells (no matrix) contain osteoblastic anabolic factors (62) . It also seems likely that additional unknown mechanisms are in play in response to this pleiotropic hormone. For example, it is difficult to envision how the foregoing mechanisms could provide accuracy in controlling both the cell number and activity for a process that can continue for #6 months (3). Perhaps, other mechanisms, such as epigenetic regulation (63), will be discovered in the future to explain the fine tuning of the regulation of bone repletion.
Mechanisms for rapid bone formation during dietary bone repletion
In the phenomenon of the rapidity of bone repletionmediated regeneration after calcium deficiency (Fig. 7,  right) , bone repletion after a calcium deficit can be more rapid than that seen with other types of bone loss, such as 2 D act on osteocytes to increase production of RANKL, which then acts on osteoclast progenitors to promote osteoclast formation and on osteoclasts to enhance their bone resorption activity, leading to increased bone resorption and bone loss. However, increased plasma PTH also acts on osteocytes to suppress Sost production, which results in an enhanced Wnt signaling in MSCs and osteoprogenitors. This would promote proliferation and osteogenic differentiation of certain MSC subpopulations. The increased plasma 1,25(OH) 2 D also promotes osteoblastic differentiation of these MSCs. In addition, bone resorption releases insulin-like growth factor 1 (IGF-1) and transforming growth factor-b (TGFb) from the resorbing bone matrix, which act on osteoprogenitors to further promote their proliferation and differentiation. Together, these effects lead to the accumulation of multilayers of osteoblastic cells at or near the bone turnover site and increases in their production of collagen to form matrices. However, the reduced plasma levels of calcium and the highly elevated 1,25(OH) 2 D, which has been shown to inhibit bone mineralization (51) , act together to prevent mineralization of the newly formed matrix, resulting in increased osteoid formation and suppression of bone formation. (Right) Plasma calcium increases after restoration of dietary calcium, which then markedly reduces plasma PTH and 1,25(OH) 2 D. Increased plasma calcium, along with a reduction in plasma PTH and 1,25(OH) 2 D, leads to increased apoptosis of osteoclasts, which results in a marked reduction in bone resorption. The departure of osteoclasts then recruits the osteoblasts that were generated during the bone depletion process to the bone remodeling sites to increase bone formation. The increased plasma calcium and normalization of plasma 1,25(OH) 2 D also promotes rapid mineralization of the existing osteoids and increases bone formation, which results in restoration of the loss of bone mass during the bone depletion phase.
immobilization (39) or glucocorticoid therapy (64) . In our study, a 40% decrease occurred in the trabecular bone volume during bone depletion, which was 100% restored, along with 100% restoration of trabecular connectivity, after only 2 weeks of bone repletion. Contributing to the rapid repair are several processes. First is the accumulation of osteoblast lineage cells during depletion, which eliminates the time required to produce these cells at the beginning of repletion. Such cells are activated immediately on switching to a normal calcium diet. Second is that the rate of bone repletion was proportional to the rate of bone resorption (3). Therefore, repair would be hastened by a severe deficiency. Finally, osteoid accumulates during depletion, and this can be mineralized to produce structural bone rapidly on normalization of plasma calcium. This would seem to constitute a good compromise in supporting plasma calcium and also minimizing adverse effects on bone.
It would seem likely that the teleological function of the anabolic effects of PTH is specifically and perhaps exclusively related to bone repletion. This is the only known physiologic phenomenon in which systemic anabolic bone activity would be required. A corollary to this concept is that the bone repletion related to lactation would be mediated by PTHrp instead of PTH (both acting on PTH1R) (65); otherwise, the two repletion models seem generally synonymous with the model illustrated in Fig. 7 .
Clinical implications of our mouse dietary bone repletion study
In an interventional study, we showed that young adults demonstrated changes in serum biomarkers consistent with bone repletion (5). Also, important evidence for functioning bone repletion in humans was the finding in a large study of primary hyperparathyroidism patients (average age 50 years), who underwent parathyroidectomy treatment and who subsequently showed a .13% gain in vertebral bone density postoperatively (9) . It is unlikely that this gain entirely resulted from a decrease in the remodeling space. Instead, it seems likely that this gain was at least in part due to the accumulation of cells of osteoblast lineage during the hyperparathyroid state. Consistent with this interpretation, the alkaline phosphatase level was slightly increased before surgery and had decreased significantly after surgery (9) .
The mechanism by which PTH therapy for osteoporosis leads to increased bone formation has not yet been established (66) . Our results raise the possibility that the pulsatile spike in plasma PTH from the subcutaneous injection of PTH would lead to activation of, not only osteoclasts, but also osteoblast precursors, which could then differentiate once the serum PTH level returns to normal.
In another clinical situation in which the PTH in serum is high is type 2 osteoporosis, also referred to as senile osteoporosis (67) . In one study of type 2 osteoporosis, serum Ocn, which is ordinarily increased with PTH therapy, was decreased (68) . Usually, in hyperparathyroidism, one sees a concomitant increase in the serum parameters of bone formation such as alkaline phosphatase and Ocn. This somewhat discrepant finding raises the possibility that the action of PTH in these patients to accumulate osteoblast lineage cells is impaired. Thus, it is possible that bone repletion could be impaired in type 2 osteoporosis and perhaps contributes to the disease.
Another clinical observation that raises the possibility of impaired bone repletion in the elderly is the finding from several studies (6-8) that calcium supplementation did not increase bone density by 2% or 3%, although the patients were severely osteoporotic. Moreover, in one study, a highly significant increase in serum PTH occurred in patients with senile osteoporosis treated with vitamin D and calcium for 2 years, without an increase in bone density, despite the normalization of serum PTH (69) . This again raises the possibility that impaired bone repletion could contribute to senile osteoporosis.
Regarding the relationship between our mouse model study and the potential clinical relevance, our study used a severe calcium depletion model (because of the advantage of large magnitude changes), which would not be expected in humans. However, previously, we have shown that a bone repletion dose response occurs to increasing decrements of calcium in the diet (3). Thus, the human condition could be affected by the accumulation of the consequences of small deficiencies over many years.
In conclusion, serum calcium homeostasis and bone repletion are two tandem regulatory mechanisms, which are engaged in response to a low calcium challenge. The function of bone repletion is to repair the bone lost after a period of calcium deficiency. Although bone repletion is well conserved in mammals, including humans, and was initially recognized several decades ago, it was largely neglected in the past, because the dominating scientific interest in bone at that time was on how the bone participated in regulating serum calcium. We have shown in the present study that bone repletion is accomplished by a unique cellular mechanism that is not found in any other organ system in the body and which has potentially important clinical implications, as would be expected from a highly conserved homeostatic mechanism. Specifically, we have shown that these two opposing homeostatic mechanisms, one for plasma calcium (serum calcium homeostasis) and the other for bone tissue volume (bone repletion), can achieve efficient corresponding endpoints in an elegantly orchestrated manner, such that, during calcium deficiency, plasma calcium is fortified from the bone store of calcium, and simultaneously an accumulation occurs of osteoblast precursor cells, which, once calcium has been returned to the diet, rapidly restores the bone that had been lost during the calcium deficiency state. This is an example of how the gene networks cooperate and compete in the struggle for life (70) .
